Rainer Krebs

TL;DR: Results in rat cardiac allografts established alloimmune response as an alternative stimulus capable of inducing vascular endothelial growth factor mRNA and protein expression in cardiomyocytes and graft-infiltrating mononuclear inflammatory cells, which suggests that these cells may function as a source of VEGF to the cells of coronary arteries.

TL;DR: Results show that VEGFR-3 participates in immune cell traffic from peripheral tissues to secondary lymphoid organs by regulating allograft lymphatic vessel CCL21 production and suggest VEG FR-3 inhibition as a novel lymphatic vessels–targeted immunomodulatory therapy for cardiac allografted rejection and arteriosclerosis.

TL;DR: The findings suggest that the antiinflammatory properties of Ang1 may offer an entirely new therapeutic approach to prevent cardiac allograft arteriosclerosis.

TL;DR: It is demonstrated that donor simvastatin treatment prevents microvascular endothelial cell and pericyte dysfunction, ischemia/reperfusion injury, and chronic rejection and suggest a novel, clinically feasible strategy to protect cardiac allografts.

TL;DR: It is suggested that an acute alloimmune response to airway targets, perhaps to epithelium, is the primary cause of OB, since CsA, with a nearly exclusive effect on the transcription of immune cytokines, entirely inhibited the generation of OB.